MediWound and Vericel win FDA paediatric label expansion for NexoBrid [Yahoo! Finance]
MediWound Ltd. - Ordinary Shares (MDWD)
Last mediwound ltd. - ordinary shares earnings: 2/25 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.mediwound.com/press-releases
Company Research
Source: Yahoo! Finance
eschar removal in paediatric patients with deep partial-thickness and/or full-thickness thermal burns. The current approval builds on MediWound's previous approval for the same indication in the adult population in January. It generated $19m in sales last year, as per MediWound's financials. GlobalData expects NexoBrid sales to maintain the upward trajectory and generate over $98m in sales by 2030. NexoBrid is a gel consisting of a sterile mixture of proteolytic enzymes, which selectively eliminate burn eschar within four hours without causing harm to surrounding viable tissue. It was developed by MediWound, with Vericel acquiring commercialisation rights to NexoBrid in North America in 2019. The FDA approval for NexoBrid was based on the positive Phase III Children Innovative Debridement Study (CIDS) (NCT02278718). The trial enrolled 145 children under 17 years of age and compared NexoBrid with the current standard of care for burns. The gel removed unhealthy tissue in the burn
Show less
Read more
Impact Snapshot
Event Time:
MDWD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MDWD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MDWD alerts
High impacting MediWound Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
MDWD
News
- MediWound to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewswire
- MediWound Ltd.'s (NASDAQ:MDWD) top owners are retail investors with 38% stake, while 28% is held by institutions [Yahoo! Finance]Yahoo! Finance
- MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal BurnsGlobeNewswire
- MediWound Ltd. (NASDAQ: MDWD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $28.00 price target on the stock.MarketBeat
- MediWound Ltd. (MDWD) Q2 2024 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
MDWD
Earnings
- 8/14/24 - Miss
MDWD
Sec Filings
- 9/10/24 - Form EFFECT
- 9/9/24 - Form 424B3
- 8/29/24 - Form F-3
- MDWD's page on the SEC website